Skip to main content

Table 1 Profiles of cases of CAA and non-CAA patients analysed by LMD-LC-MS/MS

From: Apolipoprotein E and clusterin inhibit the early phase of amyloid-β aggregation in an in vitro model of cerebral amyloid angiopathy

Number

Group

Age

Sex

Lesion of brain hemorrhage

Amyloid grading scalea

Hypertension and medication

Anticoagulants or antiplatelets

Microbleeding at MRI (T2*)

Patient number in Table 3 of [18]

A-1

CAA

66

F

R temporo-parietal

4

No

No

negative

3

A-2

CAA

80

F

L temporo-parietal

4

Yes, medication

No

NA

4

A-3

CAA

79

F

L frontal

4

No

No

NA

5

A-4

CAA

74

F

R frontal

4

Yes, medication

No

positive

6

A-5

CAA

71

F

L frontal

4

Yes, medicationb

No

positive

7

A-6

CAA

63

F

L parietal

4

No

No

negative

12

B-1

non-CAA

83

F

R putamen and frontal

0

Yes, no medication

No

negative

Not included

B-2

non-CAA

67

M

R fronto-parietal

0

Yes, no medication

No

negative

25

B-3

non-CAA

75

M

R temporo-parietal

0

No

No

NA

26

B-4

non-CAA

61

M

R frontal

0

No

No

negative

28

B-5

non-CAA

68

M

R frontal

0

Yes, medication

No

NA

27

  1. M male, F female, R right, L left, NA not applicable
  2. aPathological grading system for CAA by Greenberg SM et al. [9]
  3. bSelf-withdrawal 2 years before onset